Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

Nodular lymphocyte-predominant Hodgkin lymphoma

Written2016-04Annunziata Gloghini, Antonino Carbone
Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; annunziata.gloghini@istitutotumori.mi.it (AG); Department of Pathology Centro di Riferimento Oncologico Aviano (CRO), Istituto Nazionale Tumori, IRCCS, Aviano, Italy; acarbone@cro.it (AC)

Abstract Diagnostic characteristics of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL): nodular or nodular and diffuse proliferation of scattered lymphocyte predominant (LP) tumour cells within a background reminiscent of primary or secondary lymphoid follicles.
Six different patterns: A) 'classical' nodular, B) serpiginous/interconnected nodular, C) nodular with prominent extra-nodular LP cells, D) T-cell-rich nodular, E) diffuse with a T-cell-rich background, and F) diffuse, B-cell-rich pattern.
Typical histopathologic patterns in NLPHL include patterns A and B. Both of these patterns show a predominantly nodular growth, with LP cells located within the nodules. So called "histopathologic variants" are defined by prominent extranodular LP cells associated to patterns C to F.
"Histopathologic variants" may be associated with advanced stage disease and higher relapse rate.
Assessing "histopathologic variants" patterns in NLPHL may be useful for the management of the patients.

Keywords Nodular lymphocyte-predominant Hodgkin lymphoma; NLPHL; Immunoarchitectural patterns; Immunohistological patterns; Clinics; Pathology

(Note : for Links provided by Atlas : click)

Identity

ICD-Topo C420,C421,C424
ICD-Morpho 9659/3 Nodular lymphocyte predominant Hodgkin lymphoma
Atlas_Id 1570
Other namesLymphocyte-predominant HL

Clinics and Pathology

Disease Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a distinct subtype of Hodgkin lymphoma (HL), usually associated with an indolent course and presenting in the early stages of the disease (Anagnostopoulos et al., 2000).
Phenotype / cell stem origin Cell origin
Tumour cells are antigen-selected mutating germinal center (GC) B cells. This origin is supported by
The expression of BCL6 and CD40 by tumour cells (Carbone et al., 1995; Liso et al., 2006).
The presence of CD4+, CD57+, PD1+ T cells surrounding the tumour cells (Poppema et al., 2008).
The presence of a follicular dendritic cell meshowork within the tumour nodules (Mason et al., 1994 ; Carbone and Gloghini, 2012)
The gene expression profile (Brune et al., 2008).
Rearranged, clonal and mutated (ongoing) Ig genes of tumour cells (Marafioti et al., 1997; Küppers, 2011).
Phenotype
LP cells profile: CD45+, CD20+, CD40+, CD79a+, CD75+, BCL6+, IRF4/MUM1+, and OCT2+, BOB1+, PAX5+, PU.1+, epithelial membrane antigen+. CD15 and CD30 are usually negative (Poppema et al., 2008).
Nodules compositon: CD20+ and IgD+ small B cells, CD3+ and CD4+ T cells and histiocytes.
The background of the nodules also includes an increase in GC-derived CD57+, IRF4/MUM1+, and PD-1+ T-cells populations which form a rim around LP cells (Carbone and Gloghini, 2012).
Epidemiology About 5% of all HL cases are classified as NLPHL. Males are more commonly affected than females (male-female ratio, 3:1). The median age at presentation is about 40 years.
Clinics NLPHL is a neoplasm usually associated with a favourable clinical course despite a tendency for local recurrences.
Cytology NLPHL tumour cells are termed lymphocyte predominant (LP) cells. LP cells are large cells with multilobated nuclei and scant cytoplasm. They contain multiple, not prominent, nucleoli in contrast with typical Reed Sternberg cells of classical HL that contain huge eosinophilic nucleoli.
Pathology LP tumour cells proliferate within a nodular or nodular and diffuse background (Anagnostopoulos et al., 2000). The tumour nodules are reminiscent of a primary follicle containing spherical meshworks of follicular dendritic cells (FDCs) admixed with inflammatory cells (Mason et al., 1994).
On morphologic and immunohistologic grounds, six patterns are recognizable in NLPHL (Fan et al., 2003): A) 'classical' nodular, B) serpiginous/interconnected nodular, C) nodular with prominent extra-nodular LP cells, D) T-cell-rich nodular, E) diffuse with a T-cell-rich background, and F) diffuse, B-cell-rich pattern.
Typical histopathologic patterns in NLPHL include patterns A and B. Both of these patterns show a predominantly nodular growth, with LP cells located within the nodules. So called "histopathologic variants" include patterns from C to F and are associated to prominent extranodular LP cells or to B-cell depletion of the microenvironment (Hartmann et al. Blood, 2013).
An additional nodular pattern in which LP cells proliferate within a background reminiscent of a secondary follicle without invasion of the extranodular space has been recognized (Carbone and Gloghini, 2012; Gloghini et al., 2015).
 
Other features Virology
The neoplastic cells are usually EBV negative (Anagnostopoulos et al., 2000).
Treatment Early stage disease: treatment with local radiation provides disease control and good overall survival (Advani and Hoppe, 2015).
Locally extensive or advanced stages: paradigms used for classical HL with similar outcomes (Advani and Hoppe, 2015). Excellent response rates (but increased relapse rates) observed with single agent rituximab. Promising data observed with R-CHOP (Advani and Hoppe, 2013; Younes et al., 2014).
Relapsed disease: single agent rituximab is a reasonable choice because of excellent tolerability (Advani and Hoppe, 2015).
Evolution Transformation to diffuse large B-cell lymphoma (T-cell/histiocyte rich large B-cell lymphoma).
Prognosis Favourable clinical course despite a tendency for local recurrences (Advani and Hoppe, 2013).
Compared with "typical NLPHL", "histopathologic variants" are associated with more advanced disease and a higher relapse rate (Hartmann et al. Blood, 2013).

Genetics

Translocation involving the BCL6 protooncogene (Liso et al., 2006).
Strong NFKB activity (Küppers, 2011).
Aberrant somatic hypermutation of multiple proto-oncogenes (PIM1, RHOH (TTF), MYC, and PAX5) in a fraction of cases. Most of mutations are on the 5' untranslated regions of the genes (Liso et al, 2006).
Mutation in SOCS1 (Küppers, 2011).
BAG6 (BAT3), HIGD1A, and UBD (FAT10) gene espression (Hartmann et al. PlosOne, 2013).

Bibliography

XVIII. Management of nodular lymphocyte predominant Hodgkin lymphoma.
Advani RH, Hoppe RT.
Hematol Oncol. 2015 Jun;33 Suppl 1:90-5 (Review).
PMID 26062064
 
European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes.
Anagnostopoulos I, Hansmann ML, Franssila K, Harris M, Harris NL, Jaffe ES,Han J, van Krieken JM, Poppema S, Marafioti T, Franklin J, Sextro M, Diehl V,Stein H.
Blood 2000; 96(5): 1889-1899
PMID 10961891
 
Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis.
Brune V, Tiacci E, Pfeil I, Döring C, Eckerle S, van Noesel CJ, Klapper W, Falini B, von Heydebreck A, Metzler D, Bräuninger A, Hansmann ML, Küppers R.
J Exp Med. 2008; 205(10): 2251-2268.
PMID 18794340
 
"Intrafollicular neoplasia" of nodular lymphocyte predominant Hodgkin lymphoma: description of a hypothetic early step of the disease.
Carbone A and Gloghini A.
Hum Pathol 2012; 43(5): 619-628 (Review).
PMID 22209342
 
Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines.
Carbone A, Gloghini A, Gattei V, Aldinucci D, Degan M, De Paoli P, Zagonel V, Pinto A.
Blood. 1995; 85(3): 780-789.
PMID 7530508
 
Characterization of variant patterns of nodular lymphocyte predominant Hodgkin lymphoma with immunohistologic and clinical correlation.
Fan Z, Natkunam Y, Bair E, Tibshirani R, Warnke RA.
Am J Surg Pathol 2003; 27(10)1346-1356.
PMID 14508396
 
Immunoarchitectural patterns in nodular lymphocyte predominant Hodgkin lymphoma: pathologic and clinical implications.
Gloghini A, Bosco A, Ponzoni M, Spina M, Carbone A.
Expert Rev Hematol. 2015; 8(2): 217-223 (Review).
PMID 25487651
 
The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG).
Hartmann S, Eichenauer DA, Plutschow A, Mottok A, Bob R, Koch K, Bernd HW, Cogliatti S, Hummel M, Feller AC, Ott G, Moller P, Rosenwald A, Stein H, Hansmann ML, Engert A, Klapper W.
Blood 2013; 122(26): 4246-4252.
PMID 24100447
 
Hodgkin lymphoma
Küppers, R
Atlas Genet Cytogenet Oncol Haematol. 2011;15(6):527-528. On line version : http://AtlasGeneticsOncology.org/Anomalies/HodgkinID2068.html
 
Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma.
Liso A, Capello D, Marafioti T, Tiacci E, Cerri M, Distler V, Paulli M, Carbone A, Delsol G, Campo E, Pileri S, Pasqualucci L, Gaidano G, Falini B.
Blood. 2006; 108(3): 1013-1020.
PMID 16614247
 
Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells.
Marafioti T, Hummel M, Anagnostopoulos I, Foss HD, Falini B, Delsol G, Isaacson PG, Pileri S, Stein H.
N Engl J Med 1997; 337(7): 453-458.
PMID 9250847
 
Nodular lymphocyte predominance Hodgkin's disease. A distinct clinicopathological entity.
Mason DY, Banks PM, Chan J, Cleary ML, Delsol G, de Wolf Peeters C, Falini B, Gatter K, Grogan TM, Harris NL.
Am J Surg Pathol 1994; 18(5): 526-530.
PMID 8172327
 
Nodular lymphocyte predominant Hodgkin lymphoma.
Poppema S, Delsol G, Pileri SA, Stein H.
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele H, Vardiman JW (eds.) World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, Lyon: IARC Press, 2008: 323-325
 
Hodgkin's lymphoma.
Younes A, Carbone A, Johnson P, Dabaja B, Ansell S, Kuruvilla L.
De Vita VTJ, Lawrrence TS, Rosemberg SA (eds). De Vita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2014.
 

Citation

This paper should be referenced as such :
Gloghini A, Carbone A
Nodular lymphocyte-predominant Hodgkin lymphoma;
Atlas Genet Cytogenet Oncol Haematol. in press
On line version : http://AtlasGeneticsOncology.org/Anomalies/NodulLymphPredomClassicHodgkinID1570.html


External links

arrayMapMorph ( 9659/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
 
 
Disease databaseNodular lymphocyte-predominant Hodgkin lymphoma
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed
All articlesautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Tue Mar 14 13:54:08 CET 2017


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.